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Abstract 
Glucocorticoids are widely used in primary-care veterinary practices. The study aimed to 
quantify the usage of systemic glucocorticoids (SGC) in dogs in UK using primary-care 
treatment records recorded during 2013 in the VetCompass™ Programme. From a study 
population of 455,557 dogs, 28,472 dogs (6.2%, 95%CI 6.2-6.3) received a total of 50,971 
systemic glucocorticoid therapy events in 2013. Prednisolone represented the most frequently 
used oral preparation (27,362 events, 90.0% of oral events). Dexamethasone sodium phosphate 
was the most commonly used injectable agent (12,796 events, 62.7% of injectable events). The 
most common breed treated was Staffordshire Bull Terriers (2,236/28,472 dogs, 7.9%, 95% CI 
7.5-8.2) and within-breed prevalence of SGC usage was 2,236/32,635, 6.9%, 95% CI 6.6-7.1. 
The most commonly treated age group was dogs older than 8 years (8931/102, 450,8.7%) and 
the most commonly treated bodyweight group was 10.01 to 20.0 kg (7,918/28,472, 27.8%).  
Dexamethasone and prednisolone were the most commonly prescribed SGC. Short and 
intermediate-acting injectable SGC were more commonly used compared to long acting 
injectable SGC. Older and medium size dogs were most likely to receive SGC and certain 
breeds appeared predisposed. These data can provide a useful benchmark for glucocorticoid 
usage and highlight the benefits from “Big Data” analyses. 
 
Introduction 
Glucocorticoids are a potent class of corticosteroids that are widely used in veterinary clinical 
management as anti-inflammatory and immunosuppressive agents, which can also induce 
adverse effects (1). Additional uses include treatment for allergy/anaphylaxis, 
hypoadrenocorticism, neoplasia (lymphoma) and brain trauma (historically). The onset, 
duration and glucocorticoid potency (reflected in the dose) of effect depends on both the active 
substance and the formulation. There are several injectable and oral preparations available in 
the UK, containing corticosteroids of intermediate duration of action, such as prednisolone and 
methylprednisolone and long duration of action, such as dexamethasone. The duration of action 
of these drugs may be prolonged by their formulation (especially if injected as poorly soluble 
esters).  
Few studies have quantified and described the usage of glucocorticoids in dogs in the UK. A 
study of 3 primary-care practices in England estimated that systemic glucocorticoids (SGC) 
were prescribed for approximately 15% of all dogs that received at least one medication (2). 
Of these, 1,497 (50.8%) had oral therapy, 1,227 (42.1%) had parenteral therapy and 207 (7.1%) 
had both oral and parenteral treatment. However, this work did not evaluate the proportion of 
all dogs under veterinary care that received glucocorticoid therapy, studying only those that 
had received some form of medication, and was based on a small sample of practices. Other 
work reported systemic glucocorticoid usage specifically within primary-care treatment of skin 
disease and reported that 162 of 795 skin cases (20%) received glucocorticoids as part of their 
therapeutic management (3). These previous studies were based on a small sample size and 
may have introduced bias and limited the generalisability of results to the wider population.   
Glucocorticoid administration has been associated with various adverse effects, including 
vomiting, diarrhoea, weight gain or loss, polyuria, polydipsia, delayed wound healing, 
immunosuppression and predisposition to infection, highlighting the value of reporting on 
current usage in veterinary clinical practice (4). Long-term glucocorticoid treatment has been 
associated with increased risk of urinary tract infection (UTI) (5, 6).  
 
However, current evidence on usage levels that are generalizable to the overall caseloads seen 
in primary-care practice in the UK is currently unavailable. Routine data collection over time 
across a large group of practices participating within the VetCompass™ Programme would 
facilitate evaluation of current usage levels. This study aimed to quantify and describe the usage 
of glucocorticoids across a large group of primary-care veterinary practices in the UK and 
provide benchmark results that can assist clinical audit in general practice. The current study 
did not aim to evaluate the underlying conditions for SGC treatment.  
Materials and methods 
The study population included all dogs under primary veterinary care during 2013 at 
exclusively primary-care small animal practices participating in the VetCompass™ 
Programme. The year 2013 was selected for study because it was the latest year with that a full 
available demographic dataset at the time when this study started.  Dogs under veterinary care 
were defined as those with either i) at least one electronic patient record (EPR) episode of care 
(summary diagnosis term, free-text clinical note, treatment or bodyweight) recorded during 
2013 or ii) at least one EPR recorded both before and after 2013. The VetCompass™ 
Programme collates anonymised EPR data from primary-care veterinary practices in the UK 
for epidemiological research (7). Dataset available for the study included species, breed, date 
of birth, sex, bodyweight, neuter status and treatments administered and dispensed with 
relevant dates.  
A cohort study design was used to estimate the one-year period prevalence (2013) of systemic 
glucocorticoid (SGC) usage in dogs under veterinary care in the UK(8, 9). Assuming a UK dog 
population of 8 million dogs (10), sample size calculations estimated that a sample of 
approximately 180,000 dogs would be required to estimate an expected 5.0% level of usage of 
SGC with a precision of 0.1% at a 95% confidence level (11). Ethics approval was obtained 
from the RVC Ethics and Welfare Committee (URN 2015 1369). 
A SGC was defined as any glucocorticoid preparation administered by injection, oral tablets 
or oral suspension. Inclusion criteria for SGC usage required that the systemic glucocorticoid 
was either administered or dispensed during 2013. A comprehensive list of active substance 
and brand names for systemic glucocorticoids relevant to the UK companion animal 
veterinary market was generated by searching the Veterinary Medicines Directorate (VMD), 
British Small Animal Veterinary Association (BSAVA) formulary (12) and National Office 
for Animal Health (NOAH) veterinary products databases (13). A list of search terms was 
derived from these chemical and brand names that reliably identified usage for all systemic 
glucocorticoids within the treatment field of the VetCompass™ database (Appendix 2). 
Glucocorticoid case finding involved initial screening of the treatment fields of all dogs 
within the study population for any treatment record that may have been a SGC using these 
search terms. A list of animal unique identification codes for these candidate cases for SGC 
usage was generated and treatment data (date, drug, volume/number of tablets, dosage 
instructions) on all treatments of any type during 2013 were extracted from the overall 
VetCompass™ database to an Excel format. Duplicates from the drug field were removed 
and all remaining dispensing terms used were manually coded as SGC (yes/no) to create a 
master list of SGC dispensing terms. All treatments from every candidate dog were then 
classified as either SGC or non-SGC using this master dispensing term list to identify all dogs 
from the overall study population with at least one SGC administered or dispensed during 
2013.  
A new systemic glucocorticoid episode was defined as usage of a systemic glucocorticoid 
that was not preceded by any recorded usage of a systemic glucocorticoid during the previous 
31 days. Individual dogs could have had multiple episodes of systemic glucocorticoid usage 
during 2013. Individual episodes of systemic glucocorticoid usage could have included the 
usage of multiple systemic glucocorticoids. For every SGC administration or dispensing 
episode (individual dogs could have had multiple events), additional information was 
extracted from the EPR on the animal unique identification code and the specific systemic 
glucocorticoid chemical used along with the date of administration, drug strength and dosage 
details. Usage was described overall and also by the number of dogs receiving the different 
types of SGC therapy, count of SGC events by dog and by quantities administered or 
dispensed. 
A purebred variable categorised all dogs of recognisable breeds as ‘purebred’ and the 
remaining dogs as ‘crossbred’ (14). A breed variable included individual breeds with 300 or 
more dogs receiving at least one SGC, a grouped category of all remaining purebreds and a 
general grouping of crossbred dogs. This approach was taken to allow focus on commonly 
treated breeds and to quantify usage with reasonable levels of precision (15). A neuter 
variable described the status of the dog (neutered or entire) recorded at the final EPR. A sex 
variable categorized sex as male, female or unrecorded. Age (years) was calculated at 
December 31st, 2013 for all dogs. An age variable categorised age (years) into six groups (< 
2, 2.0 to < 4.0, 4.0 to < 6.0, 6.0 to < 8.0, > 8.0 and unrecorded). Adult bodyweight described 
the maximum bodyweight recorded during the study period for dogs older than 18 months.  
An adult bodyweight variable categorised adult bodyweight into six groups < 10.0 kg, 10.0 to 
< 20.0 kg, 20.0 to < 30.0 kg, 30.0 to < 40.0 kg, ≥ 40.0 kg, unrecorded). 
Following data checking for internal validity and cleaning, descriptive analysis was undertaken 
in Excel (Microsoft Office Excel 2013, Microsoft Corp.) and Stata 14. The one-year (2013) 
period prevalence with 95% confidence intervals (CI) described the probability of SGC usage 
at least once during 2013 for all study dogs. The CI estimates were derived from standard errors 
based on approximation to the normal distribution for disorders with ten or more events (16). 
Demographic characteristics and prevalence of SGC usage in 2013 were reported by purebred 
status, common breeds, sex, neuter, insurance, adult age and adult bodyweight with 95% CIs. 
Systemic glucocorticoid usage was classified by bodyweight and route of administration based 
on the dogs that received at least one treatment in 2013.  
Results 
The study population included 455,557 dogs under veterinary care during 2013 in the 
VetCompass™ database. Of these, 28,472 dogs received at least one SGC giving an overall 
one-year period prevalence of 6.2% (95% CI 6.2-6.3). The breeds with the highest one-year 
period prevalence of receiving at least one SGC were Staffordshire Bull Terriers 
(2,236/28,472 dogs, 7.9%, 95% CI 7.5-8.2), Labrador Retrievers  (2,075/28,472, 7.3%, 95% 
CI 7.0-7.6), West Highland White Terriers (1,720/28,472 dogs, 6.0%, 95% CI 5.8-6.3), Jack 
Russell Terriers (1,705/28,472, 6.0%, 95% CI 5.7-6.3) and Cocker Spaniels (982/28,472, 
3.4%, 95% CI 3.2-3.7) (Table 1). For these breeds, the prevalence of SGC usage within breed 
was Staffordshire Bull Terriers (2,236/32,635, 6.9%, 95% CI 6.5-7.1), Labrador Retrievers  
(2,075/33,321, 6.2%, 95% CI 6.0-6.5), West Highland White Terriers (1,720/12,017 dogs, 
14.3%, 95% CI 13.7-14.9), Jack Russell Terriers (1,705/27,691, 6.2%, 95% CI 5.9-6.4) and 
Cocker Spaniels (982/15,827, 6.2%, 95% CI 5.8-6.6) (Table 2) 
Of the SGC treated dogs with available data for the variable, 22,571/28,472 (79.3%, 95% CI 
78.8-79.7) were purebred, 16,057/28,472 (56.4%, 95% CI 55.8-57.0) were male, 
16,337/28,472 (57.4%, 95% CI 56.8-58.0) were neutered. (Table 1). From the overall 
population with available data, 22,571/340,767 (6.6%, 95% CI 6.5-6.7) were purebred; 
16,057/234,211 (6.9%, 95% CI 6.7-7.0) were male, 16,337/205,019 (8%, 95% CI 7.8-8.1) 
were neutered (Table 2) 
The most common age group that received SGC was more than 8 years [8,931/28,472 
(31.4%, 95% CI 30.8-31.9)] and the most common weight group that received SGC was 
10.01 to 20.0 kg [7,918/28,472, (27.8%, 95% CI 27.3-28.3) (Table 1). The prevalence of 
SGC usage within age group for more than 8 years category was [8,931/102,450, (8.7% 95% 
CI 8.5-8.9)] and the prevalence of SGC usage within weight group for 10.01 to 20.0 kg 
category was [7,918/91,594, (8.6%, 95% CI 8.5-8.8)]  (Table 2). 
The most common adult body weight group that received an injectable SGC was 10.1-20.0 kg 
(29.9%, 95% CI 29.0-30.8), followed by dogs that weighed 10.0 kg or less (29.7%, 95% CI 
28.9-30.6). Similarly, dogs with 10.1-20.0 kg adult bodyweight were those that most 
commonly received oral SGC treatment and those that received the combination of both oral 
and injectable SGC (31.1%, 95%CI 30.2-32.0) and (31.4%, 95% CI 29.9-32.9) respectively. 
These were followed by dogs weighing 10.0 kg or less (24.2% oral, 95% CI 23.4-25.0) and 
(26.3% oral and injectable, 95% CI, 24.9-27.7) respectively (Table 3). 
There were 50,971 unique SGC events identified during 2013 that comprised 30,570 oral and  
20,401 injectable events. Of the oral usage events, prednisolone was the most frequently used 
agent (27,362 events, 90.0% of all oral events), followed by methylprednisolone (2,978 events, 
9.7%) and prednisolone/cinchophen (205 events, 0.7%). Of the injectable events, 
dexamethasone sodium phosphate was the most commonly used injectable agent (12,796 
events, 62.7% of injectable events), followed by dexamethasone 
phenylpropionate/dexamethasone sodium phosphate (6,243 events, 30.6%), 
methylprednisolone acetate (685 events, 3.4%) and dexamethasone isonicotinate (632 events, 
3.1%) (Table 4). 
Discussion 
This study represents the largest analysis to date of primary-care usage of SGCs in dogs in the 
UK. The results highlight relatively high levels of usage of both oral and injectable 
formulations. Heavier dogs, older dogs and certain breeds were more likely to receive 
treatment. The most common oral treatments were prednisolone (90.0% of all oral SGC events) 
and methylprednisolone (9.7%). The most common injectable treatment was dexamethasone 
sodium phosphate (62.7%). 
The current study reports that 6.2% of dogs under primary veterinary care in the UK received 
at least one SGC during 2013. A previous study in England reported a higher prevalence 
(14.6%) of SGC usage, but was based on usage by dogs over a 3 year period between 2007 and 
2009 from 3 practices, and was also restricted to the subset of dogs that received at least one 
treatment of any type overall, and was therefore likely to over-represent usage levels across all 
practice-registered dogs (2). Interestingly, usage reported in the UK specific to skin conditions 
was reported to be much higher with approximately 20% of the skin cases in primary-care 
clinics receiving SGC (3). The current study analyzed all clinical records from 304 primary-
care VetCompass™ practices for all dogs under veterinary care in 2013 and aimed to give a 
more generalisable interpretation of usage. From these results it is clear systemic 
glucocorticoids are commonly used classes of drugs in primary-care practice. 
The Staffordshire Bull Terrier, Labrador Retriever and West Highland White Terrier had the 
highest usage within treated dogs and a considerably high prevalence of usage within breed 
category for the denominator population which suggests that the high prevalence of SGC usage 
in this breeds was not because of the more frequent admission of these breeds to VetCompass 
clinics. A previous study reported that the Labrador Retriever had a higher risk of osteoarthritis 
compared with cross breeds (17). Another study reported that Labrador Retriever dogs had the 
highest prevalence of pyoderma, followed by West Highland White Terrier dogs (18). Also, it 
was found that Bull Retriever dogs have an inherited high risk of acrodermatitis as a recessive 
trait, and a high risk of atopic dermatitis due to food adverse reaction (19). A study in Romania 
reported the highest risk of Malassezia dermatitis in West Highland White Terrier dogs (19). 
These conditions could potentially be treated with anti-inflammatories. Given that the most 
common clinical application of SGCs are as anti-inflammatory and immunosuppressive agents 
(1, 20), breed-based results may be useful to identify breeds that are more likely to suffer 
inflammatory conditions and therefore also contribute to ongoing efforts to understand and 
prioritise breed health (21). The current study did not aim to evaluate the underlying conditions 
for SGC treatment; further work to evaluate these conditions as well as the outcomes from 
therapy could provide further perspectives on breed health and welfare.  
Older dogs were more likely to receive systemic glucocorticoids with dogs 8 years and older 
having a prevalence of 8.7% within the age category of the whole population and 31.4 % of 
the treated dogs. This is consistent with a previous study in which dogs were found to receive 
systemic glucocorticoid therapy more than puppies and young adults (2).  These results suggest 
that inflammatory conditions are more likely to develop with age and therefore older dogs are 
most likely to require systemic glucocorticoid therapy. A previous study of Swedish dogs 
reported that 10-year-old dogs had twice the odds of inflammatory conditions compared to 2-
year-old dogs (22).  
Prednisolone was the most frequently used oral systemic glucocorticoid (90.0% of all oral SGC 
events) followed by methylprednisolone (9.7%). Prednisolone is either prescribed at anti-
inflammatory doses (0.5 to 1mg/kg/24h, tapered down to 0.25 to 0.5mg/kg/48h) or at 
immunosuppressive doses (1 to 2mg/kg/24, tapered down to 0.5mg/kg/48h or the lowest 
effective dose while assessing for clinical relapse) (12). In a previous study in a small animal 
hospital in UK, prednisolone was administered twice daily to assess the potential relapse in 
dogs with steroid responsive meningitis-arteritis (23). A previous smaller study of 3 practices 
in UK reported that, in dogs receiving oral SGCs, prednisolone (73.6%) and 
methylprednisolone (23.1%) were the most commonly used drugs (2). It is possible that 
prescribing habits are highly individual to veterinarians and to practices. This may explain the 
substantial differences between the older smaller study and the current study results, and 
highlights the benefits from ‘Big Data’ analyses of merged datasets from multiple practices to 
be more representative of usage patterns across UK practice attending-dogs. 
The current study reported that dexamethasone sodium phosphate was the most commonly 
used injectable therapeutic (62.7%). This ranking is in agreement with the earlier primary-care 
study that also reported dexamethasone sodium phosphate as the most common injectable 
therapeutic used in dogs (2). Dexamethasone sodium phosphate is used widely in veterinary 
practices because it has good efficacy and a medium duration of action (48 hours). Blood 
cortisol levels have been shown to be suppressed with dexamethasone at 24 hours following 
injection (24). Intermediate-duration injectable formulations of dexamethasone (ester of 
isonicotinate and or phenylpropionate combined with sodium phosphate) were only used in 
one third of the injections. The use of the long acting methylprednisolone acetate ester was 
rare, and the fast acting methylprednisolone sodium succinate salt was practically never used.  
The study had some limitations. As previously described, these data were not recorded 
primarily for research purposes and thus were limited by some missing data as well as reliance 
on accurate and thorough record-keeping of the clinicians (25). The study did not include the 
indication and underlying conditions for treated dogs, which could have offered a more 
complete picture to explain the patterns of usage in UK dogs. Knowledge of the prescribed 
daily doses (mg/kg) could help to define the intended therapeutic effect (high “shock” dose, 
immunosuppression, anti-inflammatory daily or alternate days) but the variable recording 
formats of dispensing events across the thousands of animals in the study (for example, start 1 
tablet twice a day reduce to 1 daily then to 1 every other day) constrained the extraction of 
these data. 
Conclusion  
In conclusion, systemic glucocorticoids constitute a commonly used element of the therapeutic 
armamentarium of primary-care practitioners, with just over 6% of dogs under veterinary care 
receiving at least one systemic glucocorticoid annually. Certain breeds such as Staffordshire 
Bull Terriers (7.9%, 95% CI 7.5-8.2), Labrador Retrievers (7.3%, 95% CI 7.0-7.6), and West 
Highland White Terriers (6.0%, 95% CI 5.8-6.3) have an especially high prevalence of 
systemic glucocorticoid usage. Older dogs and dogs with higher adult bodyweight were more 
likely to be treated with systemic glucocorticoids. Prednisolone was the most frequent oral and 
dexamethasone sodium phosphate was the most common injectable systemic glucocorticoid.  
 
  
Tables 
Table 1: Demographic characteristics and prevalence of usage in 28,472 VetCompass™ dogs that had at 
least one systemic glucocorticoid (SGC) under primary veterinary care in the UK during 2013  
Variable Category Frequency of treated dogs Prevalence (%)  
of at least one SCG  
usage (95% CI) 
Purebred status1 Crossbred 6,530 22.9 (22.4-23.4)  
 Purebred 22,571 79.3 (78.8-79.7) 
Common breeds2 Crossbred 6,530 22.9 (22.4-23.4) 
 Other purebred 5,751 20.2 (19.7-20.7) 
 Staffordshire Bull Terrier 2,236 7.9 (7.5-8.2) 
 Labrador Retriever 2,075 7.3 (7.0-7.6) 
 West Highland White Terrier 1,720 6.0 (5.8-6.3) 
 Jack Russell Terrier 1,705 6.0 (5.7-6.3) 
 Cocker Spaniel 982 3.4 (3.2-3.7) 
 Shih Tzu 967 3.4 (3.2-3.6) 
 German Shepherd Dog 927 3.3 (3-3.5) 
 Yorkshire Terrier 924 3.2 (3-3.5) 
 Cavalier King Charles Spaniel 646 2.3 (2.1-2.4) 
 Border Collie 576 2 (1.9-2.2) 
 Bichon Frise 571 2 (1.8-2.2) 
 Boxer 569 2 (1.8-2.2) 
                                                 
1 2009(0.44 %) missing values  
2 2009(0.44 %) missing values  
 Lhasa Apso 459 1.6 (1.5-1.8) 
 Golden Retriever 424 1.5 (1.3-1.6) 
 Border Terrier 419 1.5 (1.3-1.6) 
 Springer Spaniel 378 1.3 (1.2-1.5) 
 Pug 320 1.1 (1.0-1.2) 
 Chihuahua 313 1.1 (1.0-1.2) 
 Rottweiler 311 1.1 (1.0-1.2) 
Sex Female 13,043 45.8 (45.2-46.4) 
 Male 16,057 56.4 (55.8-57) 
 Unrecorded 57 0.2 (0.1-0.3) 
Neuter status Entire 9,905 34.8 (34.2-35.3) 
 Neutered 16,337 57.4 (56.8-58) 
 Unrecorded 2,915 10.2 (9.9-10.6) 
Age (years)3 < 2.0 5,170 18.2 (17.7-18.6) 
 2.0 to < 4.0 5,838 20.5 (20-21) 
 4.0 to < 6.0 4,851 17.0 (16.6-17.5) 
 6.0 to < 8.0 4,187 14.7 (14.3-15.1) 
 > 8.0 8,931 31.4 (30.8-31.9) 
 Unrecorded 180 0.6 (0.5-0.7) 
Adult bodyweight 
(kg)4 
<10.00 6,936 24.4 (23.9-24.9) 
10.01 to 20.00 7,918 27.8 (27.3-28.3) 
 20.01 to 30.00 5,009 17.6 (17.2-18) 
 30.01 to 40.00 3,723 13.1 (12.7-13.5) 
 > 40.00 2,249 7.9 (7.6-8.2) 
 Unrecorded 3322 11.7 (11.3-12) 
                                                 
3 6,175 (1.36 %)missing values  
4 123,808 (27.18 %)missing values  
 Table (2): Demographic characteristics and prevalence of usage of systemic glucocorticoid in 455,557 dogs 
from the VetCompass Programme under primary veterinary care during 2013  
Variable Category Frequency of 
treated dogs 
Total within 
category 
Prevalence within category 
(95% CI) 
Purebred status5 Crossbred 6530 112,777 0.1 
(5.6-5.9) 
 
 Purebred 22,571 340,767 6.6 
(6.5-6.7) 
Common breeds6 West Highland White 
Terrier 
1,720 12,017 14.3 
(13.7-14.9) 
 Boxer 569 6,288 9 
(8.3-9.8) 
 Bichon 571 6,607 8.6 
(8.0-9.3) 
 Border Terrier 419 5,449 7.7 
(7.0-8.4) 
 Golden Retriever 424 5,670 7.5 
(6.8-8.2) 
 German Shepherd 
Dog 
927 12,520 7.4 
(6.9-7.9) 
 Staffordshire Bull 
Terrier 
2,236 32,635 6.9 
(6.6-7.1) 
 Lhasa Apso 459 6,840 6.7 
(6.1-7.3) 
 Springer Spaniel 378 5,800 6.5 
(5.9-7.1) 
 Tzu Shih 967 15,038 6.4 
(6.0-6.8) 
 Cavalier King Charles 
Spaniel 
646 10,143 6.4 
(5.9-6.8) 
 Labrador Retriever 2,075 33,321 6.2 
(6.0-6.5) 
 Jack Russell Terrier 1,705 27,691 6.2 
(5.9-6.4) 
                                                 
5 2009(0.44 %) missing values  
6 2009(0.44 %) missing values  
 Cocker Spaniel 982 15,827 6.2 
(5.8-6.6) 
 Yorkshire Terrier 924 15,426 6 
(5.6-6.4) 
 Pug 320 5,376 6 
(5.3-6.6) 
 Rottweiler 311 5,321 5.8 
(5.2-6.5) 
 Springer English 
Spaniel 
298 5,384 5.5 
(4.9-6.1) 
 Border Collie 576 12,268 4.7 
(4.3-5.1) 
 Chihuahua 313 11,782 2.7 
(2.4-2.9) 
 Other purebred 5,751 89,364 6.4 
(6.3-6.6) 
 Crossbred 6530 112777 0.1 
(5.6-5.9) 
 
Sex Female 13,043 219,032 6 
(5.9-6.0) 
 Male 16,057 234,211 6.9 
(6.7-7.0) 
 Unrecorded 57 2,310 2.5 
(1.8-3.1) 
Neuter status Entire 9,905 178,216 5.6 
(5.4-5.7) 
 Neutered 16,337 205,019 8 
(7.8-8.1) 
 Unrecorded 2,915 72,318 4 
(3.9-4.2) 
Age (years)7 < 2.0 5,170 128,818 4 
(3.9-4.1) 
 2.0 to < 4.0 5,838 93,411 6.2 
(6.1-6.4) 
 4.0 to < 6.0 4,851 70,784 6.9 
(6.7-7.0) 
                                                 
7 6,175 (1.36 %)missing values  
 6.0 to < 8.0 4,187 53,915 7.8 
(7.5-8.0) 
  8.0 8,931 102,450 8.7 
(8.5-8.9) 
     
Adult weight (kg)8 <1 0.00 6,936 101,703 6.8 
(6.7-7.0) 
 10.01 to 20.00 7,918 91,594 8.6 
(8.5-8.8) 
 20.01 to 30.00 5,009 68,626 7.3 
(7.1-7.5) 
 30.01 to 40.00 3,723 45,749 8.1 
(7.9-8.4) 
 > 40.00 2,249 24,073 9.3 
(9.0-9.7) 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
8 123,808 (27.18 %)missing values  
Table 3. Systemic glucocorticoid usage for adult dogs (more than 18 months of age) from the VetCompass™ 
Programme that received at least one systemic glucocorticoid therapy in 2013. Results are shown overall 
and by bodyweight9 and route of administration (N = 25,835) 1 
Adult 
body 
weight 
(kg)10 
                             Route of administration  
Injectable only Oral only 
 
Both injectable and oral Total (%) 
Frequency Prevalence 
(%) within 
injectable 
(CI) 
Prevalence 
(%) within 
weight 
group (CI) 
Frequency Prevalence 
within oral 
(CI) 
Prevalen
ce within 
weight 
group 
(CI) 
Frequency Prevalence 
within 
both 
injectable 
and oral 
(CI) 
Prevalence 
within 
weight 
group 
(95% CI) 
 
 
1.22-
10.00kg 
3,226 29.7 
(28.89-
30.61) 
46.5 
(45.34-
47.68) 
2,678 24.2 
(23.4-25) 
38.6 
(37.46-
39.76) 
1,032 26.3 
(24.92-
27.67) 
14.9 
(14.04-
15.72) 
6,936  
(26.8) 
10.01-
20.00kg 
3,242 29.9 
(29.03-
30.76) 
40.9 
(5.7-6.76) 
3,442 31.1 
(30.24-
31.97) 
43.5 
(5.7-6.76) 
1,234 31.4 
(29.99-
32.89) 
15.6 
(5.7-6.76) 
7,918 
(30.6) 
20.01-
30.00kg 
2,035 18.8 
(18.03-19.5) 
40.6 
(6.15-7.55) 
2,221 20.1 
(19.33-
20.82) 
44.3 
(6.15-
7.55) 
753 19.2 
(17.95-
20.42) 
15.0 
(6.15-7.55) 
5,009 
(19.4) 
30.01-
40.00kg 
1,476 13.6 
(12.96-
14.26) 
39.6 
(5.39-6.93) 
1,687 15.2 
(14.58-
15.92) 
45.3 
(5.39-
6.93) 
560 14.3 
(13.17-
15.36) 
15.0 
(5.39-6.93) 
3,723 
(14.4) 
>40.01 
kg 
866 8.0 
(7.48-8.5) 
38.5 
(5.21-7.2) 
1,037 9.4 
(8.83-9.91) 
46.1 
(5.21-7.2) 
346 8.8 
(7.93-9.7) 
15.4 
(5.21-7.2) 
2,249 
(8.7) 
Total 
(%) 
10,845 
(42.0) 
  11,065 
(42.8) 
  3,925 
(15.2) 
          25,835 
 
 
 
                                                 
9 Bodyweight data was missing for 3322 (11%) dogs  
10 Maximum bodyweight recorded for dogs aged over 18 months  
 Table 4: Frequency of treatment events for systemic glucocorticoid active substances and strengths. Results are 
shown by method of administration (percentage for each column shown in brackets) based on 50,971 
glucocorticoid usage events recorded during 2013. 
Active substance  Route of administration 
 Injectable Oral 
Duration 
injectable 
Number of Events 
(%) 
Total mgs 
prescribed (%) 
Number of 
Events (%) 
Total mgs 
prescribed (%) 
Budesonide   
 
 
 
11 (0.04) 18 (0.003) 
Dexamethasone Isonicotinate Intermediate 632 (3.10) 945 (1.55)  
 
 
 
Dexamethasone 
Phenylpropionate and 
Dexamethasone Sodium Phosphate 
Short to 
Intermediate 
6,243 (30.60) 8,278 (13.61)  
 
 
 
Dexamethasone Sodium Phosphate Short 12,796 (62.72) 31,773.9 (52.24)  
 
 
 
Dexamethasone (other)   
 
 
 
14 (0.05) 664 (0.01) 
Methylprednisolone   
 
 
 
2,978 (9.74) 586 (8.86) 
Methylprednisolone sodium 
succinate 
Very short 45 (0.22) 2,876 (4.73)  
 
 
 
Methylprednisolone Acetate Long 685 (3.36) 16,953 (27.87)  
 
 
 
Prednisolone   
 
 
 
27,362 (89.51) 6,014,955  (90.92) 
1 mg tablets    1443 52,539 
5 mg tablets    23,116 4,896,285 
25 mg tablets    2803 1,066,131 
Prednisolone/cinchophen    205 (0.67) 13,617 (0.21) 
Total  20,401 
 
60,826 
 
30,570 
 
6,602,037 
 
 
 
 
 
 
 
 
 
 Abbreviations 
CI Confidence intervals  
SGC Systemic glucocorticoids  
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